- •This study aimed to compare the effect of long-acting injectable antipsychotics (LAIs) with oral antipsychotics (OAPs) on time to rehospitalization within 1 year of discharge in elderly patients with schizophrenia.
- •The LAIs group had a significantly lower rehospitalization rate and a significantly longer time to rehospitalization within 1 year of discharge than the OAPs group. The prescription rate of second-generation LAIs grew significantly during the study period.
- •LAIs were found superior to OAPs in preventing rehospitalization in elderly patients with schizophrenia.
The effectiveness of long-acting injectable antipsychotics (LAIs) in elderly patients with schizophrenia remains unclear. This study aimed to compare the effect of LAIs with oral antipsychotics (OAPs) on time to rehospitalization within 1 year of discharge in this population. Other factors potentially associated with time to rehospitalization and trends in LAI prescription rates during the study period were also investigated.
Patients over 60 years of age with schizophrenia discharged between 2006 and 2017 were followed for 1 year under naturalistic conditions. Survival analysis was used in the comparison between LAIs and OAPs regarding time to rehospitalization. Covariates thought to affect time to rehospitalization were also analyzed. The Cochran-Armitage trend test was used to evaluate whether a time trend existed for LAI prescription rates.
The LAIs group had a significantly lower rehospitalization rate and a significantly longer time to rehospitalization within 1 year of discharge than the OAPs group. Other factors that were associated with a longer time to rehospitalization included a shorter index hospitalization during the time of the study and fewer previous hospitalizations. No significant time trend was found for LAI prescription rates during the study period. However, the prescription rate of second-generation LAIs grew significantly.
LAIs were found superior to OAPs in preventing rehospitalization. A continuous increase in second-generation LAI prescription rate may be due to the better side-effect profile of second-generation LAIs compared to first-generation LAIs. More studies investigating the effectiveness of LAIs in elderly patients with schizophrenia are needed in the future.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Geriatric Psychiatry
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The many faces of psychosis in the elderly.Curr Opin Psychiatry. 2007; 20: 551-558
- Treatment adherence and long-term outcomes.CNS Spectr. 2007; 12: 21-26
- Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up.Pharmacopsychiatry. 2007; 40: 264-268
- Long-acting injectable antipsychotics in the elderly: guidelines for effective use.Drugs Aging. 2003; 20: 1099-1110
- Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.Am J Geriatr Psychiatry. 2009; 17: 255-263
- Is antipsychotic treatment associated with risk of pneumonia in people with serious mental illness? The roles of severity of psychiatric symptoms and global functioning.J Clin Psychopharmacol. 2019; 39 (doi:10.1097/JCP.0000000000001090.): 434-440
- Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.Eur Neuropsychopharmacol. 1998; 8: 55-66
- Depot antipsychotic drugs. Place in therapy.Drugs. 1994; 47: 741-773
- Time to rehospitalization in patients with schizophrenia receiving long-acting injectable antipsychotics or oral antipsychotics.Int J Neuropsychopharmacol. 2019; 22 (doi:10.1093/ijnp/pyz035.): 541-547
- The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Ther Adv Psychopharmacol. 2014; 4: 198-219
- The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence.J Clin Psychiatry. 2016; 77: 1-24
- Practice guideline for the treatment of patients with schizophrenia, second edition.Am J Psychiatry. 2004; 161: 1-56
- Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines.J Psychiatr Pract. 2010; 16: 306-324
- Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.Hum Psychopharmacol. 2007; 22: 505-513
- Symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone.Int Psychogeriatr. 2008; 20: 1245-1250
- Schizophrenia in the Elderly.CNS Drugs. 2000; 13: 103-115
- Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations.Drugs Aging. 2000; 17: 363-384
- Side effects of antipsychotics in the elderly.J Clin Psychiatry. 2000; 61 (discussion 50-41): 43-49
- Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, 4th ed., Text Revision.American Psychiatric Association, Washington, DC2000
- Diagnostic and Statistical Manual of Mental Disorders: DSM-5.American Psychiatric Pub, Washington, DC2013
- Depot antipsychotics: where do we stand?.Ann Clin Psychiatry. 2016; 28: 289-298
- Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer.BMC Med Res Methodol. 2010; 10: 20
- Why must some schizophrenic patients be involuntarily committed? The role of insight.Compr Psychiatry. 1989; 30: 13-17
- Long-acting injectable antipsychotics: an expert opinion from the Association des médecins psychiatres du Québec.Can J Psychiatry. 2011; 56: 367-376
- Community treatment orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission.Aust N Z J Psychiatry. 2000; 34: 801-808
- Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness.J Nerv Ment Dis. 2001; 189: 583-592
- Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes.Aust N Z J Psychiatry. 2006; 40: 596-605
- Risk factors for readmission in schizophrenia patients following involuntary admission.PLoS One. 2017; 12e0186768
- Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.Schizophr Bull. 2015; 41: 627-636
- Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia.Neuropsychiatry. 2011; 1: 275
- Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.CNS Drugs. 2002; 16: 473-484
- Factors associated with readmission to a psychiatric facility.Psychiatr Serv. 2001; 52: 1100-1102
- Factors influencing inpatient duration among insanity acquittees in a Malaysian Mental Institution.Psychiatry. 2010; 11: 25-35
- Social support and length of hospital stay among schizophrenic patients.World Appl Sci J. 2012; 19: 625-633
- Principles and Practice of Geriatric Psychiatry.2nd ed. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia2011
- Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review.Br J Psychiatry Suppl. 2009; 52: S13-S19
- A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.J Clin Psychiatry. 2010; 71: 1226-1233
- A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.J Psychopharmacol. 2010; 24: 91-98
- Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance.Curr Opin Psychiatry. 2015; 28: 216-221
- Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge.J Manag Care Spec Pharm. 2015; 21: 754-769
Published online: August 09, 2019
Accepted: August 5, 2019
Received in revised form: August 3, 2019
Received: May 7, 2019
Previous Presentation: None.
© 2019 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.